ReviewJournal of physiology and biochemistry2026
Research progress on PANoptosis in diabetic cardiomyopathy.
Review in Journal of physiology and biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PANoptosis is a novel form of cell death that combines features of pyroptosis, apoptosis, and necroptosis. This process can be induced by various stimuli and involves the integration of multiple pro-cell death components, which assemble into different types of large molecular complexes known as PANoptosomes. Its regulatory mechanism involves several upstream key molecules, including Interferon Regulatory Factor 1, Transforming Growth Factor-β-Activated Kinase 1, and Adenosine Deaminase Acting on RNA 1, which collectively contribute to the initiation and execution of PANoptosis. Targeting the associated regulatory pathways represents an effective strategy for modulating PANoptosis. Given its significant role in cardiovascular diseases, modulating the activation of PANoptosis—either through promotion or inhibition—may offer a promising approach to preventing the progression of various related conditions. This review summarizes the current understanding of PANoptosis mechanisms and recent advances in research on its critical role in diabetic cardiomyopathy. It also highlights the complex crosstalk among multiple programmed cell death pathways, aiming to provide novel insights into effective therapeutic strategies for diabetic cardiomyopathy.
Indexed as
Identifiers
42047884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.